Feature

Vizgen championing the power of spatial genomics with unprecedented transformative insight into biological systems

Closely-held Vizgen is pioneering next-generation genomics and benchmarking the spatial genomics field with its commercial MERSCOPE Platform, the industry’s first high plex in situ single-cell spatial genomics solution...

May 7, 2024

Feature

Conavi merger and financing to help ignite widespread adoption of next-generation Novasight Hybrid intravascular imaging platform

Conavi Medical’s reverse merger with Titan Medical (TSX: TMD; OTC: TMDIF), which is expected to close in July 2024, and concurrent financing are anticipated to cultivate an investor network to help fund the expansion of...

April 2, 2024

Feature

BioRestorative Therapies propelling cell-based therapies for lower back pain, Obesity, Type 2 diabetes and more

BioRestorative Therapies (NASDAQ:BRTX) is a fully integrated regenerative medicine company with preclinical and Phase 2 clinical programs focused on conditioning the bodies’ regenerative potential to treat major...

March 5, 2024

Feature

iBio fast-tracking discovery for hard-to-drug targets with precision antibody therapeutics powered by AI and machine learning

iBio (NYSEA:IBO) is developing next-generation biopharmaceuticals leveraging computational biology and 3D-modeling of epitopes enabling the discovery of new antibody treatments for hard-to-target cancers and other...

February 6, 2024

NEWS

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

Vizgen championing the power of spatial genomics with unprecedented transformative insight into biological systems

Conavi merger and financing to help ignite widespread adoption of next-generation Novasight Hybrid intravascular imaging platform

BioRestorative Therapies propelling cell-based therapies for lower back pain, Obesity, Type 2 diabetes and more

iBio fast-tracking discovery for hard-to-drug targets with precision antibody therapeutics powered by AI and machine learning

NEWS

BioRestorative expands IP protecting ThermoStem cell-based metabolic disease therapy program

FDA provides positive feedback on Appili’s ATI-1801 for CL

HOOKIPA doses first patient in Phase 2 trial of eseba-vec for head and neck cancer

CalciMedica announces late-breaking positive data from Phase 2b CARPO trial

FDA grants RMAT designation to Allogene’s ALLO-316 for patients with RCC

Shuttle doses first patient in Phase 2 trial of Ropidoxuridine for glioblastoma

JACC article highlights emerging hybrid intracoronary imaging technologies like Conavi’s Novasight

PolTREG initiates Phase 2 trial of PTG-007 targeting functional cure for children at risk of T1D

Dr. Makoto Kuro-o joins Klotho as scientific advisor

Just a few of the companies we’ve highlighted along the way

General

More